XORTX Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters

14 Nov 2024

XORTX <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <xrtx.v> expected to post a loss of 60 cents a share - Earnings Preview </xrtx.v>

XORTX Therapeutics Inc XRTX.V is expected to report results on November 15 (estimated) for the period ending December 31 2023
LSEG's mean analyst estimate for XORTX Therapeutics Inc is for a loss of C$1.84 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is "Buy".
Wall Street's median 12-month price target for XORTX Therapeutics Inc is 12.15, above its last closing price of $1.30.

This summary was machine generated November 14 at 03:51 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483894619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483894619\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2483894619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 11:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483894619","market":"us","top_or_hot":-1,"title":"XORTX Therapeutics Inc  expected to post a loss of 60 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>XORTX <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <xrtx.v> expected to post a loss of 60 cents a share - Earnings Preview </xrtx.v></title></head><body><ul><li><p>XORTX Therapeutics Inc <span>XRTX.V</span>  is expected to report results on November 15 (estimated) for the period ending December 31 2023</p></li><li></li><li><p>LSEG's mean analyst estimate for XORTX Therapeutics Inc is for a loss of C$1.84 per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is  \"Buy\".</p></li><li><p>Wall Street's median 12-month price target for XORTX Therapeutics Inc is 12.15, above its last closing price of $1.30. </p></li></ul><p>This summary was machine generated November 14 at 03:51 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XORTX Therapeutics Inc  expected to post a loss of 60 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXORTX Therapeutics Inc  expected to post a loss of 60 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-14 11:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>XORTX <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <xrtx.v> expected to post a loss of 60 cents a share - Earnings Preview </xrtx.v></title></head><body><ul><li><p>XORTX Therapeutics Inc <span>XRTX.V</span>  is expected to report results on November 15 (estimated) for the period ending December 31 2023</p></li><li></li><li><p>LSEG's mean analyst estimate for XORTX Therapeutics Inc is for a loss of C$1.84 per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is  \"Buy\".</p></li><li><p>Wall Street's median 12-month price target for XORTX Therapeutics Inc is 12.15, above its last closing price of $1.30. </p></li></ul><p>This summary was machine generated November 14 at 03:51 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XRTX","symbol_name":"XORTX Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL8N3ML02T:1","article_id":"2483894619","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483894619","pubTimestamp":1731556337,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"XORTX Therapeutics Inc  expected to post a loss of60cents a share - Earnings Preview XORTX Therapeutics Inc XRTX.V  is expected to report results on November 15 (estimated) for the period ending Decem","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XRTX":"XORTX Therapeutics Inc."},"translate_title":"Xortx Therap什锦什锦早餐预计每股亏损什锦早餐","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XRTX":0.9},"content_text":"XORTX Therapeutics Inc  expected to post a loss of 60 cents a share - Earnings Preview XORTX Therapeutics Inc XRTX.V  is expected to report results on November 15 (estimated) for the period ending December 31 2023LSEG's mean analyst estimate for XORTX Therapeutics Inc is for a loss of C$1.84 per share. The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The average consensus recommendation for the biotechnology & medical research peer group is  \"Buy\".Wall Street's median 12-month price target for XORTX Therapeutics Inc is 12.15, above its last closing price of $1.30. This summary was machine generated November 14 at 03:51 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}